<?xml version="1.1" encoding="utf-8"?>
<rdf:RDF xmlns:OMEXlib="http://omex-library.org/"
   xmlns:bqbiol="http://biomodels.net/biology-qualifiers/"
   xmlns:bqmodel="http://biomodels.net/model-qualifiers/"
   xmlns:dc="http://purl.org/dc/terms/"
   xmlns:foaf="http://xmlns.com/foaf/0.1/"
   xmlns:local="http://omex-library.org/NewOmex.omex/NewModel.rdf#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
  <rdf:Description rdf:about="http://omex-library.org/BIOMD0000000490.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00001"/>
    <bqmodel:isDescribedBy rdf:resource="local:00002"/>
    <bqmodel:isDescribedBy rdf:resource="local:00003"/>
    <bqmodel:isDescribedBy rdf:resource="local:00004"/>
    <ns1:keyword xmlns:ns1="http://prismstandard.org/namespaces/basic/2.0/">Biomodels</ns1:keyword>
    <ns2:title xmlns:ns2="http://purl.org/dc/elements/1.1/">Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors</ns2:title>
    <ns3:thumbnail xmlns:ns3="http://www.collex.org/schema#"
       rdf:resource="http://omex-library.org/BIOMD0000000490.omex/BIOMD0000000490.png"/>
    <ns4:thumbnail xmlns:ns4="http://www.collex.org/schema#"
       rdf:resource="http://omex-library.org/BIOMD0000000490.omex/curation_image.png"/>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <ns5:identifier xmlns:ns5="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1016/j.drudis.2011.10.001"/>
    <ns6:label xmlns:ns6="http://www.w3.org/2000/01/rdf-schema#">Balaji M. Agoram &amp; Oleg Demin. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. Drug Discovery Today 16, 23-24 (2011).</ns6:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <ns7:identifier xmlns:ns7="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1038/psp.2013.49"/>
    <ns8:label xmlns:ns8="http://www.w3.org/2000/01/rdf-schema#">O Demin, T Karelina, D Svetlichniy, E Metelkin, G Speshilov, O Demin, D Fairman, PH van der Graaf &amp; BM Agoram. Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors. CPT: Pharmacometrics &amp;amp; Systems Pharmacology 2, 9 (2013).</ns8:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00003">
    <ns9:identifier xmlns:ns9="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1007/s11095-011-0467-9"/>
    <ns10:label xmlns:ns10="http://www.w3.org/2000/01/rdf-schema#">Piet H. van der Graaf &amp; Neil Benson. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharmaceutical Research 28, 7 (2011).</ns10:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <ns11:identifier xmlns:ns11="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1186/1752-0509-6-141"/>
    <ns12:label xmlns:ns12="http://www.w3.org/2000/01/rdf-schema#">Tatiana A Karelina, Kirill V Zhudenkov, Oleg O Demin, Dmitry V Svetlichny, Balaji Agoram, David Fairman &amp; Oleg V Demin. Regulation of leukotriene and 5oxoETE synthesis and the effect of 5-lipoxygenase inhibitors: a mathematical modeling approach. BMC Systems Biology 6 (2012).</ns12:label>
  </rdf:Description>
</rdf:RDF>

